Is It Time to Test the Antiseizure Potential of Palmitoylethanolamide in Human Studies? A Systematic Review of Preclinical Evidence
ReviewOther animals
- Design
- Review
- Subjects
- Systematic review of animal studies; no human study found
- Dose used in the study
- Varied, in animal models
- Duration
- Not applicable
- What was measured
- Seizure frequency and severity in animal models of epilepsy and acute seizures; endocannabinoid changes; mechanisms
What the authors reported
In animal models, supplementation reduced seizure frequency and severity, in some cases similarly to antiseizure medications. Subchronic pretreatment modulated the peripheral-brain immune system more effectively. Treatment also restored endocannabinoid level changes seen during a seizure, with the authors noting potential protection against neural damage. No human study exists.
Limits of this study
Preclinical only. The title asks whether human trials should begin; none has reported. One author consults for GW Pharma outside this work.
Source
PubMed 35053844 · doi:10.3390/brainsci12010101
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.